With an initial focus on an influenza virus vaccine, the collaboration will determine if the combination of ImmuneRegen’s vaccine adjuvant compound, Viprovex, and DelSite’s unique adjuvant system, based on the polymer GelSite, can potentially augment the ability of vaccine products to produce the enhanced immune response.
Michael Wilhelm, president and CEO of ImmuneRegen, said: “Our work with DelSite supports the development of vaccines and adjuvants that can be quickly and easily self-administered.”